Meningitis vaccine indications and usage: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Meningitis vaccine}} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = http://dailymed.nlm.nih.gov/dailymed/...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Indications And Usage== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89dde472-1efb-4630-88bc-41cde216fb3a | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89dde472-1efb-4630-88bc-41cde216fb3a | publisher = | date = | accessdate = }}</ref> | MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. MENVEO is approved for use in persons 2 months through 55 years of age. | ||
MENVEO does not prevent N. meningitidis serogroup B infections.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89dde472-1efb-4630-88bc-41cde216fb3a | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89dde472-1efb-4630-88bc-41cde216fb3a | publisher = | date = | accessdate = }}</ref> | |||
Latest revision as of 15:12, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications And Usage
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. MENVEO is approved for use in persons 2 months through 55 years of age.
MENVEO does not prevent N. meningitidis serogroup B infections.[1]
References
- ↑ "http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89dde472-1efb-4630-88bc-41cde216fb3a". External link in
|title=(help)
Adapted from the FDA Package Insert.